Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Down 97.5% in February

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 1,600 shares, a decrease of 97.5% from the January 31st total of 65,000 shares. Based on an average trading volume of 440,900 shares, the days-to-cover ratio is currently 0.0 days.

Daiichi Sankyo Price Performance

Shares of OTCMKTS:DSNKY traded down $0.63 during midday trading on Friday, reaching $22.95. 283,577 shares of the company were exchanged, compared to its average volume of 228,968. The stock has a market cap of $43.80 billion and a PE ratio of 26.69. The business’s fifty day moving average is $26.22 and its two-hundred day moving average is $31.17. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06. Daiichi Sankyo has a one year low of $22.47 and a one year high of $42.48.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Friday, January 31st. The company reported $0.22 earnings per share (EPS) for the quarter. Daiichi Sankyo had a net margin of 13.62% and a return on equity of 14.53%. As a group, analysts predict that Daiichi Sankyo will post 0.73 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.